cyrilzakka/clinical-trials huggingface dataset:
Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis

Inflammatory Bowel Disease, including ulcerative colitis, is thought to result from an imbalance of pro-inflammatory and anti-inflammatory factors. As such, the majority of treatment options are directed at attempting to control the chronic inflammation and prolonging remission of clinical symptoms. Several studies have proven that curcumin has well-established anti-inflammatory properties. However, curcumin has poor bioavailability and prior studies have needed to use high concentrations in order to study the efficacy of the product. The investigators propose that a bio-enhanced preparation of curcumin will require a lower dosage to reach and affect its target tissue and will subsequently produce less adverse side effects.


Eligibility Criteria:
Inclusion Criteria:

* Patients who have mild to moderate ulcerative colitis, with a current Partial Mayo Index greater than or equal to 2 and less than or equal to 6
* Age 18 years and above
* Male or female
* Patients who have given consent and area able to follow the treatment given
* Patients who are able to record their responses in survey form at regular follow-up visits

Exclusion Criteria:

* Patients who are in remission from ulcerative colitis, or who have a Partial Mayo Index Score of 0 or 1
* Patients who have been taking azathioprine or mercaptopurine for \<12 weeks for the treatment of their ulcerative colitis
* Patients who are taking steroids or biologic agents for the treatment of their ulcerative colitis
* Patients who have severe ulcerative colitis, or who have a Partial Mayo Index Score of 7 or above
* Patients who are noncompliant with medication or regular follow up visits
* Patients who are unable to or unwilling to record their responses in survey form
* Patients with comorbid illnesses, including: Diabetes Mellitus, Stage III or above Congestive Heart Failure, chronic pancreatitis, severe liver or renal disease
* Patients who have current gallstones or any biliary dysfunction
* Patients with anemia (Hemoglobin \<10), thrombocytopenia, abnormal lymphocyte counts, or coagulation abnormalities
* Patients who currently have an ongoing severe infection/sepsis
* Patients with a history of malignancy
* Patients who are currently pregnant or nursing
* Patients who are current smokers
Latinx Teen Depression Treatment Study

The purpose of this study is determine facilitators of and barriers to receiving evidence-based psychotherapy for depression for Latinx adolescents from multiple stakeholder perspectives.


Eligibility Criteria:
Inclusion Criteria:

* Aged 13-17
* self-identify as Hispanic/Latinx
* diagnosed with Major Depressive Disorder or Persistent Depressive Disorder/Dysthymia
* referred to psychotherapy or prescribed medication for depression.

Healthcare providers:

* Self-identify as regularly providing clinical care to Latinx adolescents with depression
* be in a role in which they can refer to or provide depression treatment.

Exclusion Criteria:

* Teens will be excluded if they are experiencing intense psychological distress or imminent thoughts of suicide or have any condition in which, in the opinion of the investigator, precludes the study team from obtaining informed assent of the teen
Exercise and PRP vs Exercise Alone in Patients With Knee Osteoarthritis

This study is a prospective randomized controlled study of different treatments for knee osteoarthritis and aims to investigate the efficacy of exercise combined platelet rich plasma (PRP) injection versus only exercise or only PRP treatments.


Eligibility Criteria:
Inclusion Criteria:

* Adults 40-70 years of age,
* Grade 2-3 according to Kellgren Lawrence osteoarthritis classification,
* No medication for knee osteoarthritis in the past three months,
* Subjects who understand and sign the consent form for this study.

Exclusion Criteria:

* Patients who have received an invasive procedure, intra-articular application and / or physiotherapy in the target knee within three months,
* Previous partial or total knee replacement of the target knee,
* Body mass index \> 30 kg/m2,
* Having any cardiovascular diseases, neurological disorders, rheumatic diseases, malignancy or psychiatric diseases,
* Impaired cognition that impacts the ability to give informed consent,
* Participation in another clinical trial.
CS1P1 PET Studies of Neuroinflammation in Parkinson Disease

Parkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that results in decline in mobility and thinking. Based on prior research, the investigators think that small amounts of inflammation in the brain may contribute to the mobility and thinking problems in people with PD. They are trying to measure inflammation in the brain in order to understand how this inflammation could be contributing to the symptoms of PD. This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called \[11C\]-CS1P1 to identify inflammation in the brain.The goal of this project is to quantify neuroinflammation with \[11C\]-CS1P1 PET and compare to motor and cognitive function in participants with various stages of severity of PD compared to controls.


Eligibility Criteria:
Inclusion Criteria:

* Parkinson Disease (PD) participants must be at least 50 years old and meet clinical diagnostic criteria of idiopathic PD.
* Control participants must be at least 50 years old and not have PD, no first-degree family member with PD, and no evidence of PD or dementia on examination.

Exclusion Criteria:

* any history of other neurologic illness (e.g. stroke, seizure, multiple sclerosis)
* history of brain surgery or major head trauma
* major medical/systemic illness
* severe psychiatric illness (e.g. bipolar disorder, schizophrenia)
* major drug abuse
* history of long term use of anti-dopaminergic medication
* chronic treatment with immunomodulatory or anti-inflammatory medications
* weight over 300 lbs
* contraindication to or inability to tolerate MRI
Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

This is a phase 1 study of anti-IGF-IR CP-751,871 in patients with solid tumors currently enrolling patients 9 years old and older with Ewing's sarcoma family of tumors (Ewing's, PNET and Askin's).


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of Ewing's sarcoma family tumors

Exclusion Criteria:

* Concurrent treatment with any other anti tumor agents
Impact of Two Methods of Listening to Music During Exercise on Perceived Exertion and Overall Physical Activity

The purpose of the study is to compare two different methods of listening to music while performing aerobic exercise: synchronous music listening vs. asynchronous music listening. Synchronous music listening while exercising is a learned activity where the participant moves his or her body in synchrony with the beat of the music, similar to dancing or to participating in a group exercise (aerobics) class. Our hypothesis is that synchronous music listening reduces the level of perceived exertion to the exercise and motivates the subject to exercise more often. This study randomly assigns 46 subjects, age 20-55 years old to either a control group of listening to their own favorite music in an asynchronous fashion or to an intervention group of listening to prepared music in a synchronous fashion over a six week period.


Eligibility Criteria:
Inclusion Criteria:

* Adult employees of Georgetown University (age 20-55) who listen to music while exercising.

Exclusion Criteria::

* A major medical condition that would prevent the participant from undertaking regular exercise
* The use of beta blocker medication
* Participation in varsity sports
Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects

To investigate whether the daily glucose profiles as assessed by continuous glucose monitoring for 1 week of normal weight and obese individuals relate to hunger levels and food intake.

To evaluate the effect of blood glucose levels on eating behavior in a population of patients with diabetes in a free-living environment; the investigators plan to study lean healthy control subjects (BMI \<25 kg/m2) and obese non-diabetic subjects (BMI \> 30 kg/m2).

The participants who qualify will be invited to use the CGMS (DEXCOM G4 Platinum) for up to 7 days. On the visit for placement of the CGMS: 1) the participants will be explained by one of the study physicians how to use a glucometer (FreeStyle or Accu-Check), 2) they will have the CGMS inserted under the skin, and 3) they will be instructed how to fill up the food log (informational brochures are available at the end of the protocol. On the second visit (up to 7 days after the initial visit) the CGMS will be removed from the skin and the glucose meter and food log will be returned to the investigators.

When this study was initially designed, it incorporated 2 additional arms in the study: T1DM and obese T2DM patients. These patients were never recruited for the study.

Eligibility Criteria:
Inclusion Criteria:

* A1c \< 10.5 %

Exclusion Criteria:

* BMI \<18 (no upper limit),
* Creatinine \> 1.5 mg/dL,
* Hgb \< 10 mg/dL,
* ALT \> 2.5 X ULN,
* untreated thyroid disease,
* uncontrolled hypertension,
* known neurological disorders,
* untreated psychiatric disorders,
* use of antidepressants and psychiatric medications,
* use of weight loss medications in the 6 months prior to the study,
* malignancy,
* smoking,
* current or recent steroid use in last 3 months,
* history of current illicit drug use;
* for women: pregnancy, or breastfeeding.
A Randomized Trial Evaluating EARLY Application of a Surfactant Dressing in Thermal Injury (EARLY)

The purpose of this study is to test the following hypotheses:

1. Early use of water-soluble surfactant dressing (WSD) on partial-thickness burn wounds will result in tissue salvage and reduce surgical burden.
2. Early use of WSD on partial-thickness burn wounds will result in faster healing.
3. Use of WSD on partial-thickness burn wounds will result in less painful wound care.
4. Early use of WSD on partial-thickness burn wounds will result in less infection.
5. Early use of WSD on partial-thickness burn wounds will result in lower hospital costs.

Surfactant-based wound dressings have been utilized in chronic, non-healing wounds and small burn wounds to soften and aid removal of wound debris. In vitro data suggest enhanced healing properties are due the ability to stabilize and potentially reseal plasma membranes, thereby, retaining cellular integrity and enhance wound healing. Improved cellular viability and functionality has also been established in heat-shock, ionizing radiation, and electrical injury models. In one rat model, topically suffused mesentery demonstrated improved microvascular flow and reduction in the number of abnormally flowing microvessels following thermal injury. Intravenous administration has been studied in several disease states. In thermal injury, intravenous administration has shown potential to improve blood flow and reduce the zone of coagulation. Further, surfactant-based wound dressings are non-ionic and may facilitate removal, sensitize, or prevent bacterial biofilms. Biofilms are an evolved, protective mechanism bacteria utilize to reduce antimicrobial efficacy. Removal or penetration of biofilms is essential for bacterial eradication. There is little evidence demonstrating the efficacy of early use of a WSD for treating partial-thickness burn wounds.

Eligibility Criteria:
Inclusion Criteria:

* age ≥ 18 years old
* admitted within 24 hours of injury
* partial-thickness burn wounds on at least two non-contiguous areas of \< 10% TBSA each and not involving face, fingers, toes, and perineum
* initial management assessed to require inpatient care

Exclusion Criteria:

* chemical, electrical, or inhalation injury
* pregnant
* incarcerated
* TBSA ≥ 20%
* wound expected to heal within 7 days
* patient or authorized representative unable or unwilling to consent
* unable to consent within 24 hours of injury
Total Genotype Score, Growth, Maturation and Loading Exposure as Risk Factors for Injury in Elite Male Youth Football

A total genotype risk score was generated based on the findings of previous research for non-contact injury, non-contact muscle injury, tendon injury, ligament injury, fracture injury and apophysitis injury. This score was then compared with the incidence of injury between those with high, medium and low risk scores for each injury. The influence of different rates of growth, stages of physical maturation and loading exposure were then also included in the risk model to see if any interaction effects could be observed between genetic risk score and susceptibility to injury in different categories of growth, maturation and loading exposure.


Eligibility Criteria:
Inclusion Criteria:

* Elite male football players

Exclusion Criteria:

* Female
* non-elite
HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

HER2-low Breast cancer (BC) has emerged as a new subtype of BC with distinct clinical, pathological, and prognostic features. Little is known about the prevalence of the HER2-low subtype in HER2-negative patients, and previous reports showed variations in the criteria used to define the HER2-low subtype. Besides, data on the clinical features and prognosis of HER2-low patients are limited, and it is still unclear whether HER2-low BC has a prognostic value. Identifying the prevalence and clinical features of HER2-low BC can help establish a more accurate and reproducible definition of HER2-low BC. In the Gulf Cooperation Council (GCC) region, BC is the most common malignancy in women and still poses a significant burden on healthcare resource utilization, moreover, there is only one record for reimbursed HER2 IHC status, categorized as HER2-positive and HER2-negative. It is important to understand the prevalence, clinical features, and outcomes of HER2-low in BC patients from the GCC In this retrospective, non-interventional, multicenter study, the aim to describe the prevalence of HER2-low BC among the current HER2-negative BC population using rescored HER2 IHC samples. The local treatment patterns and the outcomes will be analyzed using the information abstracted from the corresponding medical chart review. The study will cover the GCC region countries (United Arab Emirates \[UAE\], Saudi Arabia, Qatar, Kuwait, and Oman)


Eligibility Criteria:
Inclusion Criteria:

* women ≥ 18 years of age at date of diagnosis
* Patients must have a histological or cytological confirmed diagnosis of Unresectable or/and mBC between 01st January 2018 and 31st December 2022.
* Patients with at least 12 months of follow-up data (from the index date) in the medical records at the participating site unless patient died.
* Patients must have been diagnosed as HER2-negative (HER2 IHC 0, 1+, 2+/ISH-), regardless of hormone status.
* Patients who are diagnosed and/or progressed on at least one prior systemic anticancer therapy (e.g., ET, chemotherapy, CDK4/6i, targeted therapies other than anti- HER2, or immunotherapy) in the metastatic setting.
* Patients must have historical HER2 fixed tissue IHC stained slides in acceptable quality to allow retesting of HER2 expression only in case of the absence of accurate scoring of IHC/ISH in pathology report.

Exclusion Criteria:

* Have a history of other malignancies other than basal cell carcinoma of the skin and squamous cell carcinoma of the skin.
* Patients who are HER2 positive (with historical HER2 status of IHC 2+/ISH+ or 3+, or HER2 amplified.
The Effect of Mindfulness-based Relapse Prevention on Impulsive Control Circuit Among Methamphetamine Dependents

Amphetamine-type stimulants (ATSs) have become the most important medical issue as well as the social problem. Compared with traditional drugs, ATS are highly neurotoxin and can induce cognitive deficit and psychotic symptoms. Due to lack of efficient medical treatment, psychotherapy and behavioral interventions are the main treatment strategies so far. Mindful-based relapse prevention (MBRP) which combined mindfulness with relapse prevention skills, as a novel intervention, has been widely used in prevent craving and relapse among addictions. While the current research of MBRP mechanism focus on emotion regulation circuit, and there was no study to explore the impulsive circuit, which is the important factor that induce the addiction and relapse. However, there was no report about the influence of MBRP on Prefrontal-striatal circuits. Based on the previous results, the proposed study will focus on evaluating the mechanism of MBRP on prefrontal-striatal circuits, neuropsychological tests and functional MRI will be used to investigate the neurobiological mechanism of MBRP on prefrontal-striatal circuits and related impulsive behaviors.


Eligibility Criteria:
Inclusion Criteria:

* 18-45 years old, male or female, with 9 years of education or above, can cooperate with the completion of the questionnaire evaluation;
* Comply with DSM-V diagnostic criteria for amphetamine-based addiction;
* The previous use of amphetamines for not less than 1 year (at least once a week);
* Vision and hearing are normal, or in the normal range after correction. No contraindications for magnetic resonance imaging;
* agree to cooperate with the completion of follow-up evaluation;
* The Mindfulness Attention Awareness Scale score is greater than 50 points.

Exclusion Criteria:

* Severe cognitive dysfunction, such as history of head trauma, cerebrovascular disease, epilepsy, etc., drugs used to promote cognitive function in the last 6 months; intellectual impairment IQ\<70;
* There have been other abuse or dependence of psychoactive substances in the past 5 years (excluding nicotine); 100 healthy controls have been publicly collected by the public. Exclude serious physical illness and mental damage. through
* SCID clinical interviews exclude family history of mental disorders and psychosis, no history of substance abuse (except nicotine).
A Single Center Registry of Coronary OCT

This registry started January 1,2020 to collect patients who recieve coronary OCT imaging in Hainan General Hospital.All enrolled patients will receive 1 year followed-up.

This registry started January 1,2020.Patients \>= 18 years old who recieve coronary OCT imaging in Hainan General Hospital are included in current registry.

Eligibility Criteria:
Inclusion Criteria:

* Subjects who recieved intracoronary OCT imaging during cardiac catheterization are eligible for this registry.

Exclusion Criteria:

* None
Electronic Catheter Stethoscope

This is an observational, exploratory study designed to collect (record) and analyze normal and abnormal sound data from the human bladder during surgery using a novel sensor-based catheter system (Electronic Catheter Stethoscope) and to develop algorithms to detect changes of baseline bladder and ureteral function. The Electronic Catheter Stethoscope device will measure acoustic and pressure data within the bladder. The measurements will be used to detect any leakage from the bladder and/or changes in baseline ureteral flow by correlation of sound data with surgical data reported by the surgeon. These data will be used to develop algorithms to detect changes of baseline bladder and ureteral function. The algorithms will be tested in future clinical trials.


Eligibility Criteria:
Inclusion Criteria

* age 18 or older
* plan to have one of the following types of surgery:

  * laparoscopic or abdominal gynecological surgery
  * vaginal surgery
* able to provide written informed consent

Exclusion Criteria

* under 18 years of age
* bilateral tubal ligation as the single reason for surgery
* current pregnancy
* unable to provide written informed consent
A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients 18 to 75 years of age with active RA
* Must have been taking MTX for at least 6 months
* No concurrent DMARD treatment (other than a stable dose of MTX)

Exclusion Criteria:

* Planned major surgery (e.g., joint replacement) within the duration of the treatment period of the study
* Treated with intra-articular injections of corticosteroids within 28 days prior to Day 1
Cognitive Effects of tDCS and tRNS in Schizophrenia

The purpose of this study is to investigate the cognitive effects of different electrical stimulation modalities, such as transcranial direct and random-noise stimulation over the dorsolateral prefrontal cortex, in schizophrenia.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of schizophrenia based on Diagnostic and Statistical Manual (DSM)5
* Being 18-50 years old (male and female)
* If female, negative urine pregnancy test
* feasibility for tDCS/tRNS interventions according to safety guidelines
* stable medication regime, especially for classical neuroleptics and all central nervous system activating medications, if taken, 4-6 weeks before the experiment
* fluency in the native language
* right-handed
* Required written informed consent signed by patients' guardian

Exclusion Criteria:

* pregnancy
* alcohol or substance dependence
* comorbid bipolar disorder and mood disorder
* history of seizure
* history of neurological disorder
* history of head injury
* Presence of ferromagnetic objects in the body that are contraindicated for brain stimulation of the head (pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments)